Big Money in Ligand Pharmaceuticals Inc (NASDAQ:LGND), Sentiment at 1.11

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Corporate Logo

Positions for Ligand Pharmaceuticals Inc (NASDAQ:LGND)

In Q2 2018 Ligand Pharmaceuticals Inc (NASDAQ:LGND) big money sentiment increased to 1.11, according to Securities and Exchange Commission filings. So its up 0.05, from 2018Q1’s 1.06. 139 investment managers opened new and increased holdings, while 125 sold and trimmed equity positions in Ligand Pharmaceuticals Inc so the sentiment increased. Funds own 22.99 million shares, up from 22.56 million shares in 2018Q1. Funds holding Ligand Pharmaceuticals Inc in top 10 changed to 12 from 12 for the same number . In total 16 funds closed positions, 109 reduced and 97 increased. Also 42 funds bought new Ligand Pharmaceuticals Inc stakes.

Biggest Ligand Pharmaceuticals Inc Shareholders

Knott David M owns 344,041 shares in Ligand Pharmaceuticals Inc as of Q2 2018. Ligand Pharmaceuticals Inc’s shareholder First Light Asset Management Llc owns 122,463 shares as of Q2 2018. Kopp Investment Advisors Llc reported 21,405 shares. Conestoga Capital Advisors Llc revealed 501,894 shares position in Ligand Pharmaceuticals Inc. The Connecticut-based fund Cardinal Capital Management Llc Ct holds 425,237 shares or 2.88% of their portfolio.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.The firm is valued at $3.35 billion. The Company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer.The P/E ratio is 32.09. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others.

LGND is reaching $158.59 during the last trading session, after decreased 7.36%.Ligand Pharmaceuticals Incorporated is uptrending after having risen 86.03% since November 10, 2017. LGND has 824,542 volume or 32.56% up from normal. LGND outperformed by 70.41% the S&P 500.

Rice Hall James & Ltd has 266,920 shs. Keybank Natl Association Oh owns 2,600 shs for 0% of their capital. Ima Wealth Inc invested 0% of its capital in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Moreover, Da Davidson & has 0.01% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Bogle Invest Management L P De owns 0.76% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 50,824 shs. Thrivent Financial For Lutherans accumulated 14,626 shs. Brinker reported 0.01% of its capital in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Nomura holds 5,000 shs. Raymond James Associate owns 16,245 shs. Tci Wealth Advsr invested in 0% or 18 shs. Axiom Invsts Limited Liability De reported 21,565 shs. First Quadrant L P Ca accumulated 2,039 shs. 9,348 are held by Bancorporation Of Montreal Can. Public Sector Pension Board reported 0.03% stake. Marshall Wace Llp invested 0.02% of its capital in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND).

Ligand Pharmaceuticals Incorporated registered $47.40 million net activity with 0 buys and 14 selling transactions since May 15, 2018. 34,500 shs valued at $8.35 million were sold by HIGGINS JOHN L on Thursday, August 16. Another trade for 2,500 shs valued at $518,699 was sold by KOZARICH JOHN W. Korenberg Matthew E had sold 18,357 shs worth $4.71 million on Wednesday, August 29. 4,000 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shs with value of $778,039 were sold by LAMATTINA JOHN L. On Thursday, August 16 Patel Sunil sold $10.15 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) or 42,287 shs. Aryeh Jason had sold 27,942 shs worth $6.76M.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

In total 5 analysts cover Ligand Pharmaceuticals (NASDAQ:LGND). “Buy” rating has 3, “Sell” are 0, while 2 are “Hold”. (NASDAQ:LGND) has 60% bullish analysts. 5 are the (NASDAQ:LGND)’s ratings reports on 10 Nov 2018 according to StockzIntelligence Inc. On Wednesday, June 27 the firm has “Buy” rating given by Craig Hallum. The company rating was maintained by H.C. Wainwright on Wednesday, September 19. On Wednesday, August 8 the stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) earned “Neutral” rating by Roth Capital.

For more Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news released briefly go to: Nasdaq.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Ligand Pharmaceuticals Inc (LGND) Q3 2018 Earnings Conference Call Transcript” released on November 08, 2018, “Three sell-siders bullish on Kodiak Sciences in premarket analyst action” on October 29, 2018, “3 Top Biotech Stocks to Buy Right Now” with a publish date: October 30, 2018, “Analysis: Positioning to Benefit within Ligand Pharmaceuticals, AptarGroup, Unifirst, Universal, AutoZone, and …” and the last “Ligand Pharmaceuticals beats by $0.29, beats on revenue” with publication date: November 08, 2018.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.